Ruserontinib

DB21555InvestigationalSmall molecule

Ruserontinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Ruserontinib is a tyrosine kinase inhibitor. Ruserontinib is under investigation in clinical... Ruserontinib is under investigation in clinical trial NCT04716114 (A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated).

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1, Receptor-type tyrosine-protein kinase FLT3, and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₄H₂₉N₉ · 443.559 g/mol (avg)
Code names: SKLB-1028

Resolves to

Compound

UNIIAQ3TTU8UM7CAS1350544-93-2ChEMBLCHEMBL3678958ChEBI755697PubChem54760385

Structure

InChIKeyWSOHOUHPUOAXIN-UHFFFAOYSA-NSMILESCC(C)N1C(NC2=CC=CN=C2)=NC2=CN=C(NC3=CC=C(C=C3)N3CCN(C)CC3)N=C12

Targets

P00519ABL1P36888FLT3P00533EGFR

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruserontinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account